🇺🇸 Pioglitazone + Metformin in United States
34 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 34
Most-reported reactions
- Death — 4 reports (11.76%)
- Hypoglycaemia — 4 reports (11.76%)
- Nausea — 4 reports (11.76%)
- Vomiting — 4 reports (11.76%)
- Weight Decreased — 4 reports (11.76%)
- Diarrhoea — 3 reports (8.82%)
- Drug Ineffective — 3 reports (8.82%)
- Fatigue — 3 reports (8.82%)
- Headache — 3 reports (8.82%)
- Acute Kidney Injury — 2 reports (5.88%)
Other Diabetes approved in United States
Frequently asked questions
Is Pioglitazone + Metformin approved in United States?
Pioglitazone + Metformin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pioglitazone + Metformin in United States?
Sun Yat-sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.